Holger N Lode

25PUBLICATIONS
102CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Infant and child healthRadiation therapyGene and molecular therapyHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|Oct 27, 2026
Survival Outcomes with IL-2-Free Dinutuximab Beta Treatment Strategies With or Without 13-cis-Retinoic Acid in Relapsed or Refractory Neuroblastoma: An Exploratory Unanchored, Population-Adjusted Comparison of Two Prospective Cohorts.

|Sep 28, 2026
Multicenter analysis of [123I/131I]I-mIBG imaging in pediatric neuroblastoma - effective dose estimation.

|Sep 13, 2025
Dinutuximab Beta Versus Naxitamab in the Treatment of Relapsed/Refractory Neuroblastoma in Patients with Stable Disease, Minor Response or Partial Response and Disease in Bone or Bone Marrow: Systematic Review and Matching-Adjusted Indirect Comparison.

Holger N Lode, Przemysław Holko, Aleksandra Wieczorek

|Aug 14, 2025
Affinity Affects the Functional Potency of Anti-GD2 Antibodies by Target-Mediated Drug Disposition.

Sascha Troschke-Meurer, Maxi Zumpe, Peter Moritz Ahrenberg

|Jul 08, 2025
Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial.

Holger N Lode, Nikolai Siebert, Dominique Valteau-Couanet

|Jun 13, 2025
Accelerating Drug Development for Neuroblastoma: Consensus Statement From the Third Neuroblastoma Drug Development Strategy Forum.

Steven G DuBois, Lucas Moreno, John Anderson

Pageof 5

Frequent Collaborators

11 joint publications

Sascha Troschke-Meurer

7 joint publications

Nikolai Siebert

6 joint publications

Maxi Zumpe

4 joint publications

Aleksandra Wieczorek